Our study hypothesized that CMB inhibited cell growth and tumor development of HGSOC and NSCLC in a time-dependent manner via modulating the MAPK/ERK signaling pathways, as demonstrated by inhibiting its downstream target ERK1/2. The gene discussed is MAPK3; the disease is neoplasm.